---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-001822"
form_type: "8-K"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T02:28:08.617443+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Calidi Biotherapeutics reports Q4 net loss of $4.1M; files IND for CLD-201 solid tumor trial

## Summary
- Q4 2024 net loss $4.1M ($0.27/share) vs $8.2M loss ($0.23/share) in Q4 2023.
- Full year 2024 net loss $23.8M ($2.97/share) vs $29.2M ($17.33/share) in 2023.
- Cash and restricted cash $9.8M as of Dec 31, 2024, up from $2.1M as of Dec 31, 2023.
- IND filed in March 2025 for CLD-201 Phase 1 trial in solid tumors (breast, head&neck, sarcoma).
- CLD-101 Phase 1 trial for high-grade glioma started recruiting at Northwestern; 14th patient treated at City of Hope.

## SEC filing metadata
- accession: 0001641172-25-001822
- form_type: 8-K
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000164117225001822/0001641172-25-001822-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000164117225001822/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-001822
- JSON: https://secwatch.observer/filing/0001641172-25-001822.json
- Plain text: https://secwatch.observer/filing/0001641172-25-001822.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.